{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:37:00Z","timestamp":1785235020339,"version":"3.55.0"},"reference-count":108,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer. In this study it was tested whether oxaliplatin and irinotecan and their combinations with 5-FU have an enhanced effect when treated simultaneously with ionizing radiation. In addition, it should be compared whether one combination therapy is more effective than the other. Colorectal cancer cells (HT-29) were treated with irinotecan or oxaliplatin, both alone and in combination with 5-FU, and subsequently irradiated. The cell growth, metabolic activity and proliferation of cells were investigated, and the clonogenic survival was determined. Furthermore, the assessment of radiation-induced DNA damage and the influence of the drugs and their combinations on DNA damage repair was investigated. Treatment with irinotecan or oxaliplatin in combination with 5-FU inhibited proliferation and metabolic activity as well as clonogenic survival and the DNA damage repair capacity of the tumor cells. The comparison of oxaliplatin and irinotecan with simultaneous irradiation showed the same effect of both drugs. When oxaliplatin or irinotecan was combined with 5-FU, tumor cell survival was significantly lower than with monotherapy; however, there was no superiority of either combination regimen. Our results have shown that the combination of 5-FU and irinotecan is as effective as the combination of 5-FU with oxaliplatin. Therefore, our data support the use of FOLFIRI as a radiosensitizer.<\/jats:p>","DOI":"10.3390\/ijms241210385","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T01:35:11Z","timestamp":1687311311000},"page":"10385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells"],"prefix":"10.3390","volume":"24","author":[{"given":"Bernd","family":"Frerker","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Cappel","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kriesen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Klautke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Chemnitz, B\u00fcrgerstrasse 2, 09113 Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-022X","authenticated-orcid":false,"given":"Katrin","family":"Manda","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Suedring 75, 18059 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203","volume":"24","author":"Conroy","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","article-title":"Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results\u2014EORTC 22921","volume":"23","author":"Bosset","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","article-title":"Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer","volume":"25","author":"Liersch","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_7","first-page":"29","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. The Lancet","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/CAD.0b013e328343e076","article-title":"Oxaliplatin as a radiosensitizing agent in rectal cancer","volume":"22","author":"Huerta","year":"2011","journal-title":"Anti-Cancer Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial","volume":"16","author":"Graeven","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"djv248","DOI":"10.1093\/jnci\/djv248","article-title":"Neoadjuvant 5-FU or Capecitabine Plus Radiation with or without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial","volume":"107","author":"Allegra","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/annonc\/mdx351","article-title":"Late toxicities and clinical outcome at 5 years of the ACCORD 12\/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer","volume":"28","author":"Azria","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.20.01740","article-title":"Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD","volume":"39","author":"Schmoll","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial","volume":"37","author":"Deng","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","first-page":"588","article-title":"Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II\/III rectal cancer: A 3-year follow-up study","volume":"27","author":"Jiao","year":"2015","journal-title":"Chin. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CAD.0b013e3283425c14","article-title":"Irinotecan and radiosensitization in rectal cancer","volume":"22","author":"Illum","year":"2011","journal-title":"Anti-Cancer Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-015-0360-5","article-title":"CAPIRI-IMRT: A phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer","volume":"10","author":"Cai","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2015.08.037","article-title":"A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil\/Leucovorin or Irinotecan\/S-1 in Patients with Locally Advanced Rectal Cancer","volume":"93","author":"Jung","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijrobp.2014.03.007","article-title":"Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and prognostic factors","volume":"89","author":"Nakamura","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1748-717X-8-258","article-title":"Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: Capecitabine alone versus capecitabine plus irinotecan","volume":"8","author":"Lee","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijrobp.2013.02.020","article-title":"Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer","volume":"86","author":"Mohiuddin","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12029-011-9350-5","article-title":"Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma","volume":"43","author":"Wahba","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.29.7697","article-title":"Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: Impact on long-term clinical outcomes","volume":"29","author":"Gollins","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ijrobp.2009.12.073","article-title":"Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: Long-term results of a Phase II study","volume":"79","author":"Hong","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2009.11.007","article-title":"A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: Clinical feasibility and response rate","volume":"79","author":"Sato","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.radonc.2010.02.003","article-title":"Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer","volume":"95","author":"Shin","year":"2010","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bjc.6603570","article-title":"A phase I\/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group Study","volume":"96","author":"Falk","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","article-title":"A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer","volume":"96","author":"Willeke","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/sj.bjc.6603053","article-title":"Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: Results from a phase I\/II study","volume":"94","author":"Klautke","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2005.03.6095","article-title":"Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012","volume":"24","author":"Mohiuddin","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijrobp.2006.04.007","article-title":"A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer","volume":"66","author":"Navarro","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0360-3016(02)03863-4","article-title":"Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer","volume":"55","author":"Mehta","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.clcc.2020.01.004","article-title":"The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial","volume":"19","author":"Wang","year":"2020","journal-title":"Clin. Color. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1200\/JCO.20.01932","article-title":"Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer","volume":"38","author":"Zhu","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_36","unstructured":"(2022). NCCN Guidelines. Rectal Cancer; Version 3.2022, NCCN."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Leitlinienprogramm Onkologie (2023, April 01). S3-Leitlinie Kolorektales Karzinom. Version 2.1 2019. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Kolorektales_Karzinom\/Version_2\/LL_KRK_Langversion_2.1.pdf.","DOI":"10.1055\/a-0809-8972"},{"key":"ref_38","unstructured":"Arbeitsgemeinschaft Internistische Onkologie (AIO) (2023, April 01). Consensus Statement of the AIO, the ACO, and the ARO; 2020; AIO Office Berlin, Kuno-Fischer-Stra\u00dfe 8, Germany. Available online: https:\/\/www.aio-portal.de\/stellungnahmen.html?file=files\/content\/studien\/stellungnahmen\/2020\/Stellungnahme_AIO_ACO_ARO_Rektumkarzinom%20_%2007_2020.pdf&cid=142."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/bjs.10993","article-title":"Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer","volume":"105","author":"Clifford","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clon.2015.11.002","article-title":"Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer","volume":"28","author":"Greenhalgh","year":"2016","journal-title":"Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00066-007-9000-9","article-title":"Integration of novel agents into combined-modality treatment for rectal cancer patients","volume":"183","author":"Sauer","year":"2007","journal-title":"Strahlentherapie Onkologie"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1053-4296(03)00048-1","article-title":"Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer","volume":"13","author":"Zhu","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0360-3016(99)90220-1","article-title":"Oxaliplatin: In vitro evidence of its radiation sensitizing activity\u2014Preclinical observations relevant to clinical trials. (Abstract 202)","volume":"45","author":"Blackstock","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OTT.S241367","article-title":"FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK\/ERK Signaling in Colorectal Cancer","volume":"13","author":"Chen","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.canlet.2016.12.009","article-title":"Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin","volume":"388","author":"Cerda","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.7150\/jca.20952","article-title":"ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial-Mesenchymal Transition in Colon Cancer Cells","volume":"8","author":"Guo","year":"2017","journal-title":"J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biocel.2015.12.003","article-title":"Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism","volume":"71","author":"Lin","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbrc.2014.11.039","article-title":"miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1","volume":"457","author":"Wan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3892\/ijo.2013.2140","article-title":"Notch1-dependent regulation of p27 determines cell fate in colorectal cancer","volume":"43","author":"Hristova","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2007.10.012","article-title":"Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: Does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?","volume":"86","author":"Folkvord","year":"2008","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcp.2008.04.007","article-title":"Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines","volume":"76","author":"Noordhuis","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bcp.2007.05.001","article-title":"p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells","volume":"74","author":"Toscano","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1472-8206.2007.00462.x","article-title":"Cell cycle arrest by oxaliplatin on cancer cells","volume":"21","author":"Rouillard","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1535-7163.MCT-05-0212","article-title":"Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells","volume":"5","author":"Voland","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.MCT-05-0011","article-title":"Role of p21waf1\/cip1 in effects of oxaliplatin in colorectal cancer cells","volume":"4","author":"Hata","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/02841860500247552","article-title":"In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line","volume":"44","author":"Johnsson","year":"2005","journal-title":"Acta Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/sj.bjc.6602215","article-title":"Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells","volume":"91","author":"Arango","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000069308","article-title":"Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status","volume":"64","author":"Fischel","year":"2003","journal-title":"Oncology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.34172\/jlms.2022.09","article-title":"Effects of Radiotherapy in Combination with Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells","volume":"13","author":"Ebrahimpour","year":"2022","journal-title":"J. Lasers Med. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4251\/wjgo.v12.i3.311","article-title":"Impact of preoperative chemoradiotherapy using concurrent S-1 and CPT-11 on long-term clinical outcomes in locally advanced rectal cancer","volume":"12","author":"Kimura","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_61","first-page":"1667","article-title":"Radiosensitization by irinotecan is attributed to G2\/M phase arrest, followed by enhanced apoptosis, probably through the ATM\/Chk\/Cdc25C\/Cdc2 pathway in p53-mutant colorectal cancer cells","volume":"53","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_62","first-page":"3344","article-title":"Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan","volume":"17","author":"Yin","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4161\/auto.20268","article-title":"MAPK14\/p38\u03b1 confers irinotecan resistance to TP53-defective cells by inducing survival autophagy","volume":"8","author":"Paillas","year":"2012","journal-title":"Autophagy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/hmbci-2012-0014","article-title":"Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells","volume":"10","author":"Weber","year":"2012","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0959-8049(99)00222-1","article-title":"Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines","volume":"35","author":"Mans","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(98)00205-6","article-title":"Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity","volume":"56","author":"Pavillard","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(97)01924-5","article-title":"SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids","volume":"43","author":"Omura","year":"1997","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0360-3016(00)00461-2","article-title":"Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer","volume":"47","author":"Amorino","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1749-6632.2000.tb07047.x","article-title":"p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells","volume":"922","author":"Chen","year":"2000","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_70","first-page":"1529","article-title":"Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives","volume":"57","author":"Chen","year":"1997","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1349-7006.1997.tb00369.x","article-title":"Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts","volume":"88","author":"Tamura","year":"1997","journal-title":"Jpn. J. Cancer Res. Gann"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0360-3016(96)00326-4","article-title":"Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors","volume":"36","author":"Lamond","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_73","first-page":"1720","article-title":"Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells","volume":"54","author":"Hennequin","year":"1994","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0360-3016(92)90478-Z","article-title":"Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells","volume":"24","author":"Boothman","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0360-3016(92)90865-F","article-title":"Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I","volume":"22","author":"Kim","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_76","first-page":"5813","article-title":"Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)","volume":"51","author":"Mattern","year":"1991","journal-title":"Cancer research"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.21873\/anticanres.12598","article-title":"SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1\u03b1","volume":"38","author":"Okuno","year":"2018","journal-title":"Anticancer. Res."},{"key":"ref_78","first-page":"1159","article-title":"Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan","volume":"45","author":"Meisenberg","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1007\/s13277-016-4839-y","article-title":"Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy","volume":"37","author":"Krbal","year":"2016","journal-title":"Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Park, J.M., Huang, S., Tougeron, D., and Sinicrope, F.A. (2013). MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PloS ONE, 8.","DOI":"10.1371\/journal.pone.0065369"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2013.02.015","article-title":"In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells","volume":"86","author":"Shelton","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s10637-010-9626-9","article-title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","volume":"30","author":"Davidson","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/1547691X.2012.693547","article-title":"Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential","volume":"9","author":"Frey","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1158\/1535-7163.MCT-08-0363","article-title":"Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl-2- and superoxide dismutase 2-dependent mechanism","volume":"7","author":"Priego","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0006-2952(02)01291-1","article-title":"Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line","volume":"64","author":"Arnould","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1054\/bjoc.2000.1600","article-title":"Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: Results on human colon cancer cell lines","volume":"84","author":"Fischel","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_87","first-page":"1189","article-title":"Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin","volume":"5","author":"Raymond","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_88","first-page":"121","article-title":"5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro","volume":"23","author":"Zhou","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CAD.0b013e328334b0ae","article-title":"Targeting DNA double-strand break repair: Is it the right way for sensitizing cells to 5-fluorouracil?","volume":"21","author":"Saleh","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3727\/096504005776449680","article-title":"Irinotecan\/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines","volume":"15","author":"Grivicich","year":"2005","journal-title":"Oncol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0006-3495(69)86390-3","article-title":"Radiation-induced breaks of DNA in cultured mammalian cells","volume":"9","author":"Veatch","year":"1969","journal-title":"Biophys. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1667\/0033-7587(2002)158[0486:QDOIID]2.0.CO;2","article-title":"Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody","volume":"158","author":"Sedelnikova","year":"2002","journal-title":"Radiat. Res."},{"key":"ref_94","first-page":"305","article-title":"Gamma-H2AX - a novel biomarker for DNA double-strand breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo"},{"key":"ref_95","first-page":"1517","article-title":"Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer","volume":"17","author":"Xu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"Figer","year":"2000","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR","volume":"35","author":"Louvet","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Boni","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canrad.2007.12.006","article-title":"Combining radiation with oxaliplatin: A review of experimental results","volume":"12","author":"Hermann","year":"2008","journal-title":"Cancer Radiother."},{"key":"ref_100","first-page":"37","article-title":"Camptothecin schedule and timing of administration with irradiation","volume":"15","author":"Rich","year":"2001","journal-title":"Oncology"},{"key":"ref_101","first-page":"39","article-title":"DNA topoisomerase I-targeting drugs as radiation sensitizers","volume":"13","author":"Chen","year":"1999","journal-title":"Oncology"},{"key":"ref_102","first-page":"2529","article-title":"Search for the optimal schedule for the oxaliplatin\/5-fluorouracil association modulated or not by folinic acid: Preclinical data","volume":"4","author":"Fischel","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_103","first-page":"1021","article-title":"Activity of oxaliplatin against human tumor colony-forming units","volume":"4","author":"Raymond","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_104","first-page":"114","article-title":"Camptothecin radiation sensitization: Mechanisms, schedules, and timing","volume":"12","author":"Rich","year":"1998","journal-title":"Oncology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ijrobp.2011.05.027","article-title":"Radiation Therapy Oncology Group 0247: A randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer","volume":"82","author":"Wong","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2014.09.031","article-title":"Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer","volume":"91","author":"Wong","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1023\/A:1026520812351","article-title":"Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)","volume":"11","author":"Louvet","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:57:13Z","timestamp":1760126233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":108,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210385"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210385","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}